Zacks2d agobullish
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?